Translational Breast Cancer Research's 2026 Journal Metrics Score is 3.4, ranking Q1 in Pulmonary and Respiratory Medicine and 2 other subfields. Two-year citation average from OpenAlex data, updated August 2026.
Bookmark this page — track observed submission-to-acceptance timing, FWCI and field-normalized citation data for this journal in one view.
Journal Metrics Score 2026 · 2021–2024 window citedness 1.32.
Middle 50%: 77–127 days
58 of 58 PubMed-indexed articles · 100% coverage · 2024–2025
Translational Breast Cancer Research accepts papers a median of 101 days after submission, including peer review and revisions. That is faster than 61% of comparable journals with PubMed timing data.
No journal-level APC is available in the current OpenAlex snapshot. Cost is excluded from scoring.
Paste your title to see which of this journal's published topics it overlaps with. Your title stays in your browser for this preview and is not sent anywhere.
Want ranked journals with fit reasons, risks and a submission strategy instead? See a sample AI report.
Each spoke is a 0–100 percentile within a comparable journal cohort—not a percentage grade or a single black-box rating.
8 of 146 works · same type, year & subfield
1 works · same type, year & subfield
Below field-year expectation
of 2,435 topic-associated OpenAlex sources by lifetime output
FWCI compares papers with the same publication year, type, and field. 1.0 is the world average; above 1.0 is above expectation. This journal's median is 0.23, so its typical recent paper runs about 77% below its field benchmark.
5.5% of recent papers rank in the global top 10% after field normalization. This is easier to compare across specialties than raw citation totals.
Volume is separated from citation accumulation so newer papers are not presented as weaker simply because they are newer.
OpenAlex source records · 2020–2025
146 OpenAlex works · 2021–2024
OpenAlex topics show the research communities this journal serves.
Candidates share at least one OpenAlex subfield (or field, if too few do) with this journal's main research topics, ignoring generic catch-all topics, and are ordered by topic overlap, then current Journal Metrics Score.
* Cost is indicative only. APCs, taxes, waivers, and member discounts can change—always verify on the journal's official website.
| Category | Quartile |
|---|---|
| Cancer Research | Q2 |
| Pulmonary and Respiratory Medicine | Q1 |
| Oncology | Q1 |
| Pathology and Forensic Medicine | Q1 |
Yes. A Q1 journal by citation data
Yes. By citation data, Translational Breast Cancer Research is a strong journal: it is Q1 in Pulmonary and Respiratory Medicine and 2 other subfields and ranks #246 of 897 Oncology journals by Journal Metrics Score (top 28%). Translational Breast Cancer Research's 2026 Journal Metrics Score is 3.4. Recent papers took a median of 101 days from submission to acceptance, according to PubMed dates. OpenAlex classifies its papers in subfields including Cancer Research, Pulmonary and Respiratory Medicine, and Oncology, so check that your topic fits its scope.
Verdict from citation data only: quartile and field rank by Journal Metrics Score (OpenAlex), publisher-reported acceptance rates, and PubMed submission and acceptance dates. See how we rank journals and how to verify indexing.
Confirm the exact title and ISSNs against the publisher homepage before a high-stakes submission decision.
Source: the current OpenAlex source record. OpenAlex works can include multiple work types. Fully Open Access is a source-level flag. Recent OA Works is summed from OpenAlex's counts_by_year series (up to the latest ten years); it is not a lifetime OA percentage. Any APC shown here is an indicative OpenAlex value—verify current charges on the journal's official website.
OpenAlex classifies Translational Breast Cancer Research's papers in subfields including Cancer Research, Pulmonary and Respiratory Medicine, and Oncology. Read the aims and scope page and a few recent papers close to your topic before you prepare the manuscript.
Article types, word and figure limits, reference style, and the required statements (data availability, ethics, conflicts of interest, author contributions) are set by the journal. Prepare the cover letter and files to match them.
Translational Breast Cancer Research homepage ↗Use the submit link in Translational Breast Cancer Research's author guidelines; AME Publishing Company runs the submission site. Every author usually needs an ORCID iD, and the corresponding author needs an account on the submission site.
OpenAlex has no article processing charge on record. Check the journal website for page charges or an optional open-access fee.
Recent accepted papers took a median of 101 days from submission to acceptance, including revisions (PubMed dates). Translational Breast Cancer Research does not publish an acceptance rate.
New on PubMed
Type a topic to see the newest PubMed papers from the past week and the big picture of what they found, summarized by Claude on the Pro plan. Get a free weekly email to keep up.
See a demo:GLP-1CRISPRLong COVID
Reviewer Two · coming soon
An AI pre-submission report on your manuscript: the objections a tough reviewer is likely to raise, desk-rejection risks, and better-fit journals from our data. $29 per report.
See what the report coversYes. By citation data, Translational Breast Cancer Research is a strong journal: it is Q1 in Pulmonary and Respiratory Medicine and 2 other subfields and ranks #246 of 897 Oncology journals by Journal Metrics Score (top 28%). Translational Breast Cancer Research's 2026 Journal Metrics Score is 3.4. Recent papers took a median of 101 days from submission to acceptance, according to PubMed dates. OpenAlex classifies its papers in subfields including Cancer Research, Pulmonary and Respiratory Medicine, and Oncology, so check that your topic fits its scope.
Translational Breast Cancer Research's 2026 Journal Metrics Score is 3.4, from the August 2026 data release. The score is a two-year citation average computed from OpenAlex (CC0) data: citations received in the most recent complete year to works published in the two prior years, divided by the number of those works.
We have not found an official acceptance rate published by Translational Breast Cancer Research or its publisher, and Journal Metrics does not estimate one because submission counts are not public. What recent PubMed records do show is speed: accepted papers took a median of 101 days from submission to acceptance. To judge selectivity, compare Translational Breast Cancer Research's quartile and score with similar journals, or ask the editorial office.
Translational Breast Cancer Research's best quartile is Q1. By OpenAlex subfield: Q2 in Cancer Research; Q1 in Pulmonary and Respiratory Medicine; Q1 in Oncology; Q1 in Pathology and Forensic Medicine. Quartiles rank journals by Journal Metrics Score within each subfield.
No. Journal Metrics computes the score independently from OpenAlex open data. Other providers use different citation databases, document types, and counting rules, so their published figures for Translational Breast Cancer Research will not match this score exactly. Compare journals using one source at a time.
Translational Breast Cancer Research accepts papers a median of 101 days after submission across 58 recent PubMed records with both dates; the middle half took 77–127 days. This includes peer review, editorial handling, and revisions.
PubMed records when a manuscript was received and accepted, not the individual review stages, so peer review time on its own is not available. The full time from submission to acceptance at Translational Breast Cancer Research, which includes peer review and revisions, has a median of 101 days. For the time to a first decision, check the journal's own website.
Translational Breast Cancer Research's median of 101 days from submission to acceptance is faster than 61% of comparable journals with PubMed timing data.
Comparable journals include Npj Breast Cancer, Breast Cancer Research and Treatment, Breast Cancer, and Breast. Compare their scores, acceptance times, and costs in the recommended alternatives on this page before choosing where to submit.
Submit online through the link in Translational Breast Cancer Research's author guidelines on the journal homepage. Before submitting, check the scope, follow the author guidelines for article type, length, and required statements, and prepare a cover letter. Accepted papers took a median of 101 days from submission to acceptance in recent PubMed records.